マクロファージのコレステロール代謝におけるPitavastatinの影響

DOI Web Site Web Site 参考文献27件

書誌事項

タイトル別名
  • Effect of Pitavastatin on Macrophage Cholesterol Metabolism
  • マクロファージ ノ コレステロール タイシャ ニ オケル Pitavastatin ノ エイキョウ

この論文をさがす

抄録

  [Objectives] Pitavastatin is the first totally synthetic HMG-Co A reductase inhibitor in Japan that significantly reduces LDL cholesterol while raising HDL cholesterol. Clinical trial showed that pitavastatin has potent effects for LDL cholesterol lowering and is expected effectively to prevent atherosclerosis. To clarify the mechanism of reduction of atherosclerosis by pitavastatin, we examined the effect of pitavastatin on foam cell formation of RAW264.7 macrophages. [Methods & Results] Macrophages were cultured with pitavastatin for 24 h and exposed to oxidized LDL with pitavastatin for 3 days. Pitavastatin decreased the cellular cholesteryl ester content in a dose-dependent manner, and this effect was not via inhibition of HMG-CoA reductase because the 3-30 nM pitavastatin did not inhibit [14C]cholesterol synthesis from [14C]acetic acid and the effect was not influenced by addition of mevalonic acid. Pitavastatin increased neutral cholesterol esterase (NCEase) activity and did not affect ACAT activity, and decreased the expression of CD36 and ABCA1 mRNA. The mechanism of the increase of NCEase activity was that pitavastatin directly modified the substrate state, which was cholesterol oleate emulsified with lecithin. [Conclusion] Clinical blood concentrations of pitavastatin prevent foam cell formation of RAW macrophages by oxidized LDL, and this was not via inhibition of HMG-CoA reductase, and modify substrate condition.<br>

収録刊行物

  • 薬学雑誌

    薬学雑誌 128 (3), 357-363, 2008-03-01

    公益社団法人 日本薬学会

参考文献 (27)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ